



# The Paediatric Regulation

Paediatric Team  
Scientific Advice, Paediatrics  
& Orphan Drugs Sector  
EMA  
2007

# The current situation

- 20% of the EU population, i.e. 100 million, is aged less than 16 years
  - ⇒ premature neonate, term neonate, infant, child, adolescent
- 50-90% of paediatric medicines have not been tested and evaluated

## Risks:

- *adverse effects (overdosing)*
- *inefficacy (underdosing)*
- *improper formulation*
- *delay in access to innovative medicines*



# The paediatric background

- “A child is not a small adult”
- Clinical trials in children are more difficult, take longer and cost more; said to be unethical
- Children require specific formulations
- Paediatric indications are not profitable
- Liability of use in children

*Studies of medicinal products are performed by industry mostly in young adults, but not in children*



# Objectives of the Regulation

- Improve the health of children
  - Increase high quality, ethical **research** into medicines for children
  - Increase **availability** of authorised medicines for children
  - Increase **information** on medicines
- Achieve the above
  - Without unnecessary studies in children
  - Without delaying authorisation for adults




# Main pillars of the Regulation

- An expert committee:  
the Paediatric Committee (PDCO)
- An agreed (evolving) paediatric development:  
the Paediatric Investigation Plan (PIP)
- A set of rewards and incentives
  - For new and on-patent products
  - For off-patent products
- A series of other tools for information,  
transparency, and stimulation of research

# Paediatric Committee (PDCO)

CHMP members (5)

Patient/family and health-care professionals (3 + 3)



Experts from National Competent Authorities (22) + 2 EEA

# Paediatric Investigation Plan

- Is basis for the development and authorisation of a medicinal product for the paediatric population subsets
  - Includes details of the timing and the measures proposed to demonstrate:
    - Quality
    - Safety
    - Efficacy
- Marketing  
Authorisation  
criteria
- Is to be agreed upon and/or amended by the Paediatric Committee (PDCA)
  - Is binding on company



# Paediatric Investigation Plan Guideline?

**A Commission Guideline** *under preparation:*

Includes modalities on

- PIP requests
- Waiver requests
- Deferrals
- Key elements for PIP Decision
- Proposal for Significant Studies
- Compliance check





# PIP request outline


- Information (administrative, condition, product)
- Waiver request
- Overall strategy for development in children
- Details of individual studies
- Proposed timelines (and request for deferral)
- References



# Paediatric needs


- Preliminary lists established by Paediatric Working Party (PEG), on EMEA web
- To be reviewed by Paediatric Committee in 2007
- Update of Paediatric needs by Paediatric Committee on basis of inventory (2009) following survey by Member States

# Overview PIP procedure




OE= oral explanation

# Applicant's request for a Waiver



NB: full waiver= no reward

# Applicant's request for a PIP



NB: full waiver= no reward

# New products

- **Currently unauthorised products**
  - Obligation to submit results compliant with agreed Paediatric Investigation Plan (PIP) at time of marketing authorisation (or invalid application)
  - **Reward:** 6-month extension of the patent protection (Supplementary Protection Certificate) - if compliance, authorisation in all Member States, and information in Product Information

# Recent products


- **Authorised products with a patent**
  - Obligation to submit results compliant with agreed Paediatric Investigation Plan (PIP) at time of new indication, new route of administration, or new formulation (or invalid application)
  - **Rewards:** 6-month extension of the patent protection (Supplementary Protection Certificate) / 1-year extension of the market protection - if compliance, authorisation in all Member States, and information in Product Information

# Orphan drugs

- 15-20% of rare diseases only affect children, 55% affect both adult and children (orphan designation data)
- 2 years of market exclusivity added to existing 10 years



# Timing Consultation of Paediatric Committee




# ‘Old’ products

## Off-patent products (Optional Procedure)

- Paediatric Use Marketing Authorisation (PUMA)
  - Covers Paediatric indication and Formulation
  - Need for Paediatric Investigation Plan and Compliance
- **Reward:** 10 years data protection/exclusivity
- Brand name can be retained

# Compliance check: Possible scenarios (new products)






# Paediatric Scientific Advice

- Free of charge from entry into force
- Prior to submission of a PIP or during PIP implementation process
- Including advice on pharmacovigilance and risk management systems
- Not binding on Paediatric Committee
- Link Paediatric Committee / Scientific Advice Working Party

# Paediatric Committee and other groups





# A European Network - a tool

## EMEA Paediatric Research Network

- To link together existing networks, investigators and centres with specific paediatric expertise
- Build up competences at a European level
- Facilitate the conduct of studies
- Avoid duplication of studies



# Funding of paediatric research

- Community funding for studies into off-patent medicinal products
  - From Framework Programme(s)
  - FP7: in second call (dead line for bids: second half of 2007)
  - 30 million Euros for the 2 first years
  - Link with identified Needs and Priorities for research into off patent medicines (EMEA website)



# Transparency Measures

- **Database of Paediatric Trials (EudraCT)**
  - Protocols
  - Results
  - Studies previously performed (+/- published)
- **Database of authorised Products in EU (EudraPharm)**
  - Link to results of studies
- **Medicinal Product information (waivers & deferrals, compliance, results)**
- **Name and Praise/Name and Shame by European Commission**



## Other measures

- Inventory of use in children in Member States
- Inventory of Paediatric Needs by Paediatric Committee
- Symbol on any medicinal product authorised for children (pre and post Regulation)
- Obligation to market, or Transfer of MA or consent to use data if product withdrawn from the market



# Timeline of Implementation

- **Immediate (as of Entry into force, 26 January 2007)**
  - Free Scientific Advice
- **6 months from entry into force (26 July 2007)**
  - Establishment of Paediatric Committee
  - Submission of PIP request
  - Paediatric Use Marketing Authorisation provisions apply
- **18 months from entry into force (26 July 2008)**
  - Obligation to submit results of studies according to agreed PIP with applications for Marketing Authorisation (new products)
  - Or EMEA decision granting a waiver or deferral
- **24 months from entry into force (26 January 2009)**
  - Obligation to submit results of studies according to agreed PIP with application for new indications, new routes of administration, new pharmaceutical forms
  - Or EMEA decision granting a waiver or deferral



# Conclusions

... better medicines for children!